Verus Capital Partners LLC Has $593,000 Holdings in Pfizer Inc. (NYSE:PFE)

Verus Capital Partners LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 32.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 21,184 shares of the biopharmaceutical company’s stock after buying an additional 5,165 shares during the quarter. Verus Capital Partners LLC’s holdings in Pfizer were worth $593,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Gilbert & Cook Inc. raised its stake in Pfizer by 3.8% during the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 945 shares during the period. Los Angeles Capital Management LLC lifted its holdings in shares of Pfizer by 3.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 29,864 shares of the biopharmaceutical company’s stock worth $860,000 after purchasing an additional 899 shares in the last quarter. TCI Wealth Advisors Inc. lifted its holdings in shares of Pfizer by 4.7% in the 4th quarter. TCI Wealth Advisors Inc. now owns 15,227 shares of the biopharmaceutical company’s stock worth $438,000 after purchasing an additional 682 shares in the last quarter. Apollon Wealth Management LLC increased its stake in Pfizer by 4.7% during the 4th quarter. Apollon Wealth Management LLC now owns 188,601 shares of the biopharmaceutical company’s stock valued at $5,430,000 after purchasing an additional 8,457 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 8.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock worth $2,985,783,000 after buying an additional 8,473,686 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, August 19th. UBS Group lifted their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Trading Up 1.0 %

NYSE PFE opened at $29.01 on Tuesday. The stock has a market capitalization of $164.39 billion, a price-to-earnings ratio of -483.50, a PEG ratio of 1.02 and a beta of 0.69. The business’s fifty day moving average is $29.01 and its 200-day moving average is $28.03. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a one year low of $25.20 and a one year high of $36.29.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the firm earned $0.67 EPS. The company’s revenue was up 2.1% compared to the same quarter last year. Equities research analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.79%. Pfizer’s payout ratio is -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.